Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 10, 2026, 3:47 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 93 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Enzyme Inhibitors Clear all
Completed Phase 3 Interventional Results available

A Study of Intravenous Zanamivir Versus Oral Oseltamivir in Adults and Adolescents Hospitalized With Influenza

NCT01231620
View directory record Official record
Conditions
Influenza, Human
Interventions
Zanamivir, Placebo to match zanamivir, Oseltamivir, Placebo to match oseltamivir
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
16 Years and older
Enrollment
626 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
40
States / cities
Birmingham, Alabama • Phoenix, Arizona • Chula Vista, California + 37 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2018 · Synced Jun 10, 2026, 3:47 PM EDT
Completed No phase listed Observational

A Retrospective Analysis of the Use of ACE-inhibitors and Angiotensin Receptor Blockers

NCT00321945
View directory record Official record
Conditions
Atrial Fibrillation, Atrial Flutter
Interventions
ACE-Inhibitors and Angiotensin Receptor Blockers
Procedure
Lead sponsor
Emory University
Other
Eligibility
18 Years to 65 Years
Enrollment
546 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
3
States / cities
Atlanta, Georgia • Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 26, 2013 · Synced Jun 10, 2026, 3:47 PM EDT
Completed Phase 2 Interventional Results available

A 2-Period Crossover Study of BPN14770 in Adults Males With Fragile X Syndrome

NCT03569631
View directory record Official record
Conditions
Fragile X Syndrome, FXS, Fra(X) Syndrome
Interventions
BPN14770, Placebo
Drug
Lead sponsor
Tetra Discovery Partners
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 18, 2024 · Synced Jun 10, 2026, 3:47 PM EDT
Completed Phase 4 Interventional Results available

A Study of the Structure and Function of the Retina in Adult Patients With Refractory Complex Partial Seizures Treated With Vigabatrin (Sabril®)

NCT01278173
View directory record Official record
Conditions
Adult Refractory Complex Partial Seizures
Interventions
Sabril
Drug
Lead sponsor
Lundbeck LLC
Industry
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
22
States / cities
San Francisco, California • New Haven, Connecticut • Dover, Delaware + 19 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2016 · Synced Jun 10, 2026, 3:47 PM EDT
Completed No phase listed Observational

ACEI or ARB and COVID-19 Severity and Mortality in US Veterans

NCT04467931
View directory record Official record
Conditions
Hypertension, COVID
Interventions
ACEI/ARB, Non-ACEI/ARB, ACEI, ARB
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
22,213 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 27, 2021 · Synced Jun 10, 2026, 3:47 PM EDT
Terminated Phase 2 Interventional Results available

Rhubarb and Angiotensin Converting Enzyme Inhibitor

NCT00672451
View directory record Official record
Conditions
Diabetic Kidney Disease
Interventions
rhubarb extract, placebo
Dietary Supplement
Lead sponsor
Wake Forest University
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 12, 2018 · Synced Jun 10, 2026, 3:47 PM EDT
Completed Phase 3 Interventional Results available

Blinded Safety & Efficacy Placebo Controlled Study of Icatibant for Angiotensin Converting Enzyme Inhibitor Induced Angioedema

NCT01919801
View directory record Official record
Conditions
Angiotensin Converting Enzyme Inhibitor Induced Angioedema
Interventions
Icatibant, Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years and older
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
43
States / cities
La Jolla, California • Washington D.C., District of Columbia • Gainesville, Florida + 31 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2021 · Synced Jun 10, 2026, 3:47 PM EDT
Completed Phase 1Phase 2 Interventional

A Study to Evaluate Safety, Tolerability and Pharmacokinetics of Two Different Doses of Alpha1-Proteinase Inhibitor Subcutaneous (Human) 15% in Participants With Alpha1-Antitrypsin Deficiency

NCT04722887
View directory record Official record
Conditions
Alpha1-Antitrypsin Deficiency
Interventions
Alpha-1 15%, Liquid Alpha1-Proteinase Inhibitor (Human)
Biological
Lead sponsor
Grifols Therapeutics LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
5
States / cities
Los Angeles, California • Gainesville, Florida • Miami, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2025 · Synced Jun 10, 2026, 3:47 PM EDT
Completed No phase listed Observational

Prospective Observational Study Of Patients With Polycythemia Vera In US Clinical Practices (REVEAL)

NCT02252159
View directory record Official record
Conditions
MPN (Myeloproliferative Neoplasms)
Interventions
Not listed
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
2,544 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
264
States / cities
Green Valley, Arizona • Safford, Arizona • Scottsdale, Arizona + 261 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2021 · Synced Jun 10, 2026, 3:47 PM EDT
Completed No phase listed Observational

The Fabrazyme® and Arbs and ACE Inhibitor Treatment (FAACET) Study

NCT00446862
View directory record Official record
Conditions
Fabry Disease, Proteinuria
Interventions
enalapril and other angiotensin converting enzyme inhibitors; losartan and other angiotensin receptor blockers
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years to 85 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
5
States / cities
Birmingham, Alabama • Atlanta, Georgia • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2013 · Synced Jun 10, 2026, 3:47 PM EDT
Recruiting Phase 2 Interventional

Cardioprotection in AML

NCT04977180
View directory record Official record
Conditions
AML, Acute Myeloid Leukemia
Interventions
Cardioprotection
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Jun 10, 2026, 3:47 PM EDT
Terminated Phase 2 Interventional

Study of FibroGen (FG)-3019 in Subjects With Type 2 Diabetes Mellitus and Kidney Disease on ACEi and/or ARB Therapy

NCT00913393
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Diabetic Nephropathy, Diabetic Kidney Disease
Interventions
FG-3019, Placebo
Drug
Lead sponsor
Kyntra Bio
Industry
Eligibility
18 Years to 75 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
28
States / cities
Tempe, Arizona • Buena Park, California • Lakewood, California + 25 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2019 · Synced Jun 10, 2026, 3:47 PM EDT
Recruiting Phase 2 Interventional

Losartan to Reduce Radiation Induced Fibrosis in Breast Cancer Patients

NCT05637216
View directory record Official record
Conditions
Radiation Induced Fibrosis
Interventions
Losartan 25 milligram capsule, Placebo
Drug
Lead sponsor
Shaw Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Edwards, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Jun 10, 2026, 3:47 PM EDT
Recruiting Phase 3 Interventional

A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease

NCT06679140
View directory record Official record
Conditions
COVID-19 SARS-CoV-2 Infection
Interventions
ibuzatrelvir, placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years and older
Enrollment
2,330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
84
States / cities
Little Rock, Arkansas • Bakersfield, California • Huntington Park, California + 61 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Jun 10, 2026, 3:47 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Effect of ACE-inhibitors on Aortic Stiffness in Elderly Patients With Chronic Kidney Disease

NCT00874432
View directory record Official record
Conditions
Cardiovascular Disease, Chronic Kidney Disease
Interventions
angiotensin converting enzyme inhibitor, lisinopril
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
60 Years to 89 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 26, 2020 · Synced Jun 10, 2026, 3:47 PM EDT
Recruiting Phase 3 Interventional

A Non-inferiority Pharmacokinetic and Safety/Tolerability Study of Two Different Doses of Weekly SC Alpha1-PI 15% Compared With Corresponding Standard IV Alpha1-PI in Participants With Alpha1-Antitrypsin Deficiency (AATD)

NCT07555483
View directory record Official record
Conditions
Alpha 1 Antitrypsin Deficiency
Interventions
Alpha-1 15%, Liquid Alpha1-PI
Drug · Other
Lead sponsor
Grifols Therapeutics LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
10
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 7 more
Source: ClinicalTrials.gov public record
Updated May 31, 2026 · Synced Jun 10, 2026, 3:47 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug Interaction Study of Apixaban With Cyclosporine and Tacrolimus

NCT03083782
View directory record Official record
Conditions
Venous Thromboembolism, Pharmacokinetics, Healthy
Interventions
Apixaban alone, Cyclosporine, Tacrolimus, Apixaban
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 10, 2017 · Synced Jun 10, 2026, 3:47 PM EDT
Completed Phase 4 Interventional Results available

An Examination of the Blood Pressure Lowering Ability and Safety of Olmesartan Medoxomil in Elderly Patients With Hypertension

NCT00412932
View directory record Official record
Conditions
Hypertension
Interventions
Olmesartan medoxomil, Olmesartan medoxomil/hydrochlorothiazide
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
65 Years and older
Enrollment
178 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
29
States / cities
Birmingham, Alabama • Mesa, Arizona • Long Beach, California + 26 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2009 · Synced Jun 10, 2026, 3:47 PM EDT
Terminated Phase 3 Interventional Results available

VA NEPHRON-D: Diabetes iN Nephropathy Study

NCT00555217
View directory record Official record
Conditions
Kidney Disease, Nephropathy, Type 2 Diabetes
Interventions
losartan, lisinopril
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years and older
Enrollment
1,448 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
30
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Loma Linda, California + 27 more
Source: ClinicalTrials.gov public record
Updated May 28, 2015 · Synced Jun 10, 2026, 3:47 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine

NCT04334148
View directory record Official record
Conditions
COVID-19
Interventions
Hydroxychloroquine, Placebo oral tablet
Drug
Lead sponsor
Adrian Hernandez
Other
Eligibility
18 Years and older
Enrollment
1,360 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
34
States / cities
Aurora, Colorado • Gainesville, Florida • Jacksonville, Florida + 27 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2021 · Synced Jun 10, 2026, 3:47 PM EDT
Terminated Phase 1 Interventional Results available

A FIH Study of PF-07284890 in Participants With BRAF V600 Mutant Solid Tumors With and Without Brain Involvement

NCT04543188
View directory record Official record
Conditions
Malignant Melanoma, Carcinoma, Non-Small-Cell Lung, Brain Neoplasms, Primary, Brain Neoplasms, Malignant Neoplasms
Interventions
PF-07284890, Binimetinib, Midazolam
Drug
Lead sponsor
Pfizer
Industry
Eligibility
16 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
39
States / cities
Duarte, California • San Francisco, California • Orlando, Florida + 23 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2025 · Synced Jun 10, 2026, 3:47 PM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Evaluation of Ecallantide for the Acute Treatment of Angiotensin Converting Enzyme Inhibitor Induced Angioedema

NCT01036659
View directory record Official record
Conditions
Angioedema
Interventions
ecallantide - Kallikrein inhibitor that blocks the production of bradykinin
Drug
Lead sponsor
Bernstein, Jonathan A., M.D.
Individual
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
3
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 8, 2012 · Synced Jun 10, 2026, 3:47 PM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

The Use of Ambulatory Blood Pressure Monitors to Assess Angiotensin Converting Enzyme Inhibitors

NCT02623036
View directory record Official record
Conditions
Hypertension, Resistant to Conventional Therapy
Interventions
Equivalent dose enalapril, Equivalent dose lisinopril
Drug
Lead sponsor
Memorial Health University Medical Center
Other
Eligibility
18 Years to 79 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Savannah, Georgia
Source: ClinicalTrials.gov public record
Updated May 24, 2017 · Synced Jun 10, 2026, 3:47 PM EDT
Completed Phase 3 Interventional

Ramipril and Hydrochlorothiazide Alone and in Combination for the Treatment of Essential Hypertension

NCT00355589
View directory record Official record
Conditions
Hypertension, Blood Pressure, High
Interventions
Ramipril and hydrochlorothiazide
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
60
States / cities
Birmingham, Alabama • Huntsville, Alabama • Glendale, Arizona + 51 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2012 · Synced Jun 10, 2026, 3:47 PM EDT